Plus Therapeutics (NASDAQ:PSTV) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.28 EPS.

Separately, Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Plus Therapeutics Price Performance

PSTV stock traded down $0.09 on Friday, hitting $1.17. 133,322 shares of the company were exchanged, compared to its average volume of 62,785. The stock has a market capitalization of $6.90 million, a price-to-earnings ratio of -0.37 and a beta of 0.69. Plus Therapeutics has a twelve month low of $1.15 and a twelve month high of $2.78. The business’s fifty day moving average is $1.40 and its two-hundred day moving average is $1.67.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.71) EPS for the quarter. The firm had revenue of $1.28 million during the quarter. Equities research analysts expect that Plus Therapeutics will post -2 earnings per share for the current year.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.